aTYR PHARMA INC
ATYR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001339970
No open-market purchases or sales by aTYR PHARMA INC insiders were filed in the last 90 days; 89 institutions reported holding it in 13F filings for Q2 2026, worth $23.2M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding aTYR PHARMA INC changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Of which not filed for Q4 2021 | Q4 2021 | Change |
|---|---|---|---|---|
| Holders | 42 | 1 | 47 | +6 |
| Shares | 19.0M | 130.6K | 20.6M | +1.73M (+9.2%) |
| Value | $172.1M | $1.19M | $153.5M | −$17.4M (−10.2%) |
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held aTYR PHARMA INC at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Tikvah Management LLC | 1,225,833 | $9.16M | 2.55% |
| Deep Track Capital, LP | 1,100,000 | $8.22M | 0.61% |
| Gsa Capital Partners LLP | 58,791 | $439.0K | 0.06% |
| Raymond James & Associates | 24,584 | $184.0K | 0.00% |
| Nan Fung Group Holdings Ltd | 23,500 | $176.0K | 0.05% |
| Morgan Stanley | 20,465 | $153.0K | 0.00% |
| Goldman Sachs Group Inc | 18,512 | $138.0K | 0.00% |
| Trexquant Investment LP | 18,106 | $135.0K | 0.01% |
| Ameriprise Financial Inc | 16,700 | $125.0K | 0.00% |
| Jump Financial, LLC | 16,100 | $120.0K | 0.01% |
| Blueshift Asset Management, LLC | 12,729 | $95.0K | 0.01% |
| Qube Research & Technologies Ltd | 11,665 | $87.0K | 0.00% |
| Charles Schwab Investment Management Inc | 10,000 | $75.0K | 0.00% |
| UBS Group AG | 1,132 | $8.00K | 0.00% |
| Royal Bank of Canada | 500 | $4.00K | 0.00% |
| PFS Partners, LLC | 406 | $3.03K | 0.00% |
| RE Dickinson Investment Advisors, LLC | 300 | $2.00K | 0.00% |
Sold out (11)
Institutions that held aTYR PHARMA INC at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Virtu Financial LLC | 143,677 | $1.30M |
| Jane Street Group, LLC | 136,901 | $1.24M |
| Susquehanna International Group, LLP | 81,781 | $743.0K |
| Boothbay Fund Management, LLC | 56,329 | $511.0K |
| Price T Rowe Associates Inc | 12,024 | $109.0K |
| Sheaff Brock Investment Advisors, LLC | 11,000 | $100.0K |
| Group One Trading, L.P. | 2,022 | $18.0K |
| Bank of America Corp | 382 | $3.00K |
| Carmichael Hill & Associates, Inc. | 300 | $3.00K |
| Ironwood Financial, llc | 50 | $0 |
| Advisor Group Holdings, Inc. | 1 | $0 |
Not filed for Q4 2021 yet (1)
Institutions that held aTYR PHARMA INC at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 130,572 | $1.19M |